

Special Issue

Immunology and Vaccines against Avian Infectious Diseases

Message from the Guest Editors

Avian immunology is still in the early stages compared to the advancement and knowledge of mammalian immune systems. In addition, infections of microbial pathogens are a problem to avian health and cause an economic challenge primarily to the poultry industry. Furthermore, the effectiveness of vaccination is compromised due to continuing evolution of some of the pathogens and the emergence of new variants. To overcome these hurdles and develop effective control and preventive measures, clear insight into the host immune responses against infectious diseases and vaccines is essential. This Special Issue focuses on recent research progress in host immune responses, vaccine-mediated immune responses, and host-microbial interaction in avian species. It will provide an opportunity to share the evolving knowledge on avian immunology, microbiology, and vaccinology in the aspect of infectious diseases to scholars working in this area. Besides, this issue will also consider the developing knowledge on the avian immune system and other immune-related conditions affecting the avian host.



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4

CiteScore 9.9

Indexed in PubMed



[mdpi.com/journal/vaccines](https://www.mdpi.com/journal/vaccines)

Vaccines

Editorial Office

MDPI, Grosspeteranlage 5

4052 Basel, Switzerland

Tel: +41 61 683 77 34

vaccines@mdpi.com

[mdpi.com/journal/vaccines](https://www.mdpi.com/journal/vaccines)

Guest Editors

Dr. Alexander Yitbarek

Department of Animal Science, McGill University, 2111 Lakeshore Road, Ste-Anne-de-Bellevue, QC H9X 3V9, Canada

Dr. Jegarubee Bavananthasivam

Human Health Therapeutics, National Research Council Canada, 100 Sussex Dr., Ottawa, ON K1A 0R6, Canada

Deadline for manuscript submissions

closed (31 March 2023)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](http://mdpi.com/journal/vaccines)

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

